Human CellExp™ 4-1BB / TNFRSF9, Fc Tag, Human Recombinant

Biomolecule/Target: TNFRSF9

Synonyms: TNFRSF9,4-1BB,CD137,CDw137,ILA

Alternates names: TNFRSF9,4-1BB,CD137,CDw137,ILA

Taglines: A transmembrane cytokine

Taglines: USA

Country of Animal Origin: USA

NCBI Gene ID #.: 3604

NCBI Gene Symbol: TNFRSF9

Gene Source: Human

Accession #: Q07011

Recombinant: Yes

Source: HEK 293 cells

Purity by SDS-PAGE #: ≥95%

Assay: SDS-PAGE

Purity: N/A

Assay #2: N/A

Endotoxin Level: < 1 EU/μg

Activity (Specifications/test method): Measured by its binding ability in a functional ELISA

Biological activity: Immobilized Human 4-1BB, Fc Tag at 0.1 μg/mL (100 μL/well) can bind Biotinylated Human 4-1BB Ligand, Fc Tag, Avi Tag with a linear range of 0.4-13 ng/mL

Results: N/A

Binding Capacity: Immobilized Human 4-1BB, Fc Tag at 0.1 μg/mL (100 μL/well) can bind Biotinylated Human 4-1BB Ligand, Fc Tag, Avi Tag with a linear range of 0.4-13 ng/mL

Unit Definition: N/A

Molecular Weight: 43.3 kDa

Concentration: N/A

Appearance: Lyophilized

Physical form description: Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH 7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution Instructions: Reconstitute in sterile deionized water to a concentration of 50 µg/ml.

Background Information: 4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF. responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF

Amino acid sequence: N/A

Handling: Centrifuge the vial prior to opening.

Usage: For Research Use Only! Not to be used in humans